AMRX (Amneal Pharmaceuticals) Inventories, Finished Goods: $349 Mil (As of Mar. 2026)


AMRX Amneal Pharmaceuticals Inc AMRX
63 GF Score
Price $17.16
GF Value $7.58
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Amneal Pharmaceuticals Inventories, Finished Goods?

Amneal Pharmaceuticals AMRX +1.00% 63 Inventories, Finished Goods is $349 Mil as of Mar. 2026. GuruFocus rates AMRX with a GF Score™ of 63/100 and a GF Value™ of $7.58 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Amneal Pharmaceuticals's quarterly finished goods declined from Sep. 2025 ($341 Mil) to Dec. 2025 ($323 Mil) but then increased from Dec. 2025 ($323 Mil) to Mar. 2026 ($349 Mil).

Amneal Pharmaceuticals's annual finished goods increased from Dec. 2023 ($304 Mil) to Dec. 2024 ($352 Mil) but then declined from Dec. 2024 ($352 Mil) to Dec. 2025 ($323 Mil).

Amneal Pharmaceuticals Inventories, Finished Goods Historical Data

* Premium members only.

The historical data trend for Amneal Pharmaceuticals's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amneal Pharmaceuticals Inventories, Finished Goods Chart

Amneal Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Finished Goods
Get a 7-Day Free Trial Premium Member Only Premium Member Only 227.08 247.61 304.08 351.92 323.49

Amneal Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 335.21 342.67 341.29 323.49 349.41
AMRX
63GF Score
Amneal Pharmaceuticals Inc AMRX
Inventories, Finished Goods is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amneal Pharmaceuticals Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

What does a Inventories, Finished Goods of $349 Mil mean?
Amneal Pharmaceuticals (AMRX) has a Inventories, Finished Goods of $349 Mil as of Mar. 2026. Finished goods are inventory items that are complete and ready to be sold. View historical data on Amneal Pharmaceuticals and its competitors.
Is Amneal Pharmaceuticals' Inventories, Finished Goods too high?
Amneal Pharmaceuticals' current Inventories, Finished Goods is $349 Mil. Overall, Amneal Pharmaceuticals has a GF Score™ of 63/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Amneal Pharmaceuticals' Inventories, Finished Goods compare to INDV and KNSA?
Amneal Pharmaceuticals' Inventories, Finished Goods of $349 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Finished Goods for a Drug Manufacturers company?
A good Inventories, Finished Goods depends on the Drug Manufacturers industry context. However, Inventories, Finished Goods should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Finished Goods mean?
A high Inventories, Finished Goods can signal that a stock is expensive relative to its fundamentals. Finished goods are inventory items that are complete and ready to be sold. View historical data on Amneal Pharmaceuticals and its competitors. Amneal Pharmaceuticals's current Inventories, Finished Goods is $349 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amneal Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Amneal Pharmaceuticals (AMRX) is currently considered Significantly Overvalued. The stock's GF Value™ is $7.58, compared to a current price of $17.16 — trading 126.3% above its estimated fair value. The current Inventories, Finished Goods is $349 Mil. Amneal Pharmaceuticals' overall GF Score™ is 63/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Finished Goods calculated?
Inventories, Finished Goods is calculated from a company's financial statements. For Amneal Pharmaceuticals (AMRX), the current Inventories, Finished Goods is $349 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Amneal Pharmaceuticals (AMRX) Overvalued in 2026?

Based on GuruFocus' analysis, Amneal Pharmaceuticals stock appears to be overvalued. The current stock price of $17.16 is trading 126.3% above its estimated GF Value™ of $7.58. GuruFocus considers Amneal Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for AMRX:

  • Inventories, Finished Goods: $349 Mil
  • GF Value™: $7.58 vs. price of $17.16 (126.3% above fair value)
  • GF Score™: 63/100 with 6 warning signs

No single metric tells the full story. See the AMRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Amneal Pharmaceuticals Business Description

Other Exchanges 2DT:Germany
Address 400 Crossing Boulevard, 3rd Floor, Bridgewater, NJ, USA, 08807
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
63GF Score

Get the complete analysis for AMRX

Inventories, Finished Goods is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$17.16
Price
$7.58
GF Value